Understanding the varied impact of COVID-19 in Shanghai and Hong Kong: A comparative analysis

NewsGuard 100/100 Score

Announcing a new article publication for Zoonoses journal. Shanghai and Hong Kong, China, experienced an outbreak of COVID-19 in early 2022. Both cities had similar dynamic prevention policies and population-level immunity but showed differences in the numbers of cases and deaths.

Data was collected from official websites to estimate and compare the infection rates, mortality rates, and infection fatality ratios (IFRs) between cities. Univariable analysis was performed, and two tree models were used to explore the factors affecting the differences.

The infection rate in Hong Kong, China, was 42.45 (95% CI: 42.41-42.48) per 100 individuals (15.49 times higher than that in Shanghai). The mortality rate was 124.90 (95% CI: 122.33-127.46) per 100,000 individuals (51.61 times higher than that in Shanghai). The adjusted IFR was 0.29% (95% CI: 0.29-0.30%) (3.30 times higher than that in Shanghai). The infection rate was negatively correlated with the stringency of nonpharmaceutical interventions. The mortality rate and IFR negatively correlated with the vaccination rate. However, positive correlations were observed between the median age and both mortality and IFR, as well as between the proportion of people ≥65 and IFR.

Overall, a lack of medical resources, lower vaccination rates, and higher median age were associated with a higher infection rate, mortality rate, and IFR in Hong Kong.

Source:
Journal reference:

Sun, R., et al. (2024). Factors Associated with the Clinical Severity and Disease Burden of COVID-19 Caused by Omicron BA.2 in Shanghai and Hong Kong, China. Zoonoses. doi.org/10.15212/zoonoses-2023-0055.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Paxlovid enhances treatment options for COVID-19 patients